Navigation Links
Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
Date:2/28/2008

developing ANA773 as a novel therapy for patients with cancer. We anticipate identifying the dose and schedule for Phase II investigation by the end of this year."

About ANA773

ANA773 is an orally administered prodrug of a novel TLR7-specific agonist. Pharmacology studies have shown that ANA773 can elicit desired immune responses and components of the response can be modulated by both dose and schedule of administration.

Data presented at the AACR-NCI-EORTC meeting in October 2007 showed that activation of TLR7 by the biologically active metabolite of ANA773 initiates a cascade of immune stimulatory events that has the potential to mediate anti-tumor activity by the induction of cytolytic activity by CD8 T cells against tumor cells and cytolytic activity of NK cells against tumor cells directly or through antibody-dependent cellular cytotoxicity (ADCC). Anadys also demonstrated that the immunostimulatory responses can be modulated by schedule of administration. Earlier in 2007, data presented at the AACR meeting showed that ANA773 and its active metabolite stimulate secretion of interferon alpha and other cytokines as well as enhance rituximab-mediated ADCC against transformed B cells.

About TLR7 agonists in cancer therapy

The potential benefits of the TLR7 mechanism in cancer therapy arise from the fundamental role of this receptor in immune activation. The host immune system, once activated, plays an essential role in controlling the ability of cancer cells to grow, invade and metastasize. Immunotherapy has had some success in treating selected tumors, and the potential to harness the immune system as a therapeutic modality remains of great interest to many oncologists.

TLR7 agonists are of particular interest because there is precedent for their use in cancer. Small molecule ligands for this receptor have been identified, including topical imiquimod (Aldara(R)) which is approved for the treatment of basal cell carcinoma i
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
4. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
7. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
8. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
11. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... from the National Institute of Standards and Technology ... demonstrated a new design for an atomic clock ... or a microcomb. , The microcomb clock, featured ... the new journal Optica ,* is the ... and its accurate conversion of optical frequencies to ...
(Date:7/22/2014)... July 22, 2014 CTD Holdings, Inc. ... pharmaceutical, medical device, cosmetics, and other markets, announced today ... a group of qualified private investors led by Novit ... , The transaction involved the signing of a ... shares of Common Stock at a price per share ...
(Date:7/22/2014)... NJ (PRWEB) July 22, 2014 ... precision, portable, and mechanical balances and scales, proudly ... balances has won Laboratory Equipment magazine’s 2014 “Readers' ... the second consecutive year the Explorer was voted ... The annual Readers’ Choice Awards celebrates “excellence in ...
(Date:7/22/2014)... and SHENZHEN, China , July ... LTD, (BGI Tech), a subsidiary of BGI, the ... launch of a new human whole exome sequencing ... newly offered service includes in-depth bioinformatics analysis and ... until December 31, 2014. Complete ...
Breaking Biology Technology:'Comb on a chip' powers new NIST/Caltech atomic clock design 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3
... 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a ... affordable vaccines based on proprietary manufacturing technologies and ... been awarded a proof of concept contract by ... laboratory specifically the Edgewood Chemical Biological Center ("ECBC") ...
... Guacamole is a little prettier in October as your ... "Pink" Guacamole. Nielsen-ranked, top-selling Wholly Guacamole, is for the ... proceeds from October "PINK" sales to help fight for ... of Texas-Based Wholly,s support for National Breast Cancer Awareness ...
... ... ... October 8, 2009 -- iCardiac Technologies, Inc., a global leader in advanced cardiac core ... iCardiac a comprehensive cardiac safety study. iCardiac will provide end-to-end study management, equipment ...
Cached Biology Technology:Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy 2Grocery Produce Fighting for a Cause - Wholly 'Pink' Guacamole 2Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2
(Date:7/23/2014)... fatty acids and energy to infants and children ... that soybean-based emulsions could compromise immune functions and ... lipid emulsions based on triglyceride oil, fish oil, ... this concern. , However, researchers at Rutgers and ... according to a review published today in the ...
(Date:7/22/2014)... consists of both still images and video of ... research. Forty-four still images were chosen from more ... staff, and alumni representing more than 25 different ... than 50 submissions. , Zach Donnell, a graduate ... 2014 organizers, noted that the exhibit highlights the ...
(Date:7/22/2014)... BEDFORD, Mass., July 22, 2014 Aware, Inc. (NASDAQ: ... and services, today reported financial results for its second quarter ... quarter of 2014 was $6.8 million, an increase of 53% ... Operating income before patent related income in the second quarter ... the second quarter of 2013. The increase in revenue and ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... be taken during radiation therapy treatments because they ... normal prostate cell lines, leading to normal tissue ... issue of the International Journal of Radiation ... Society for Radiation Oncology (ASTRO). Many prostate cancer ...
... The Society for Nutrition Education (SNE) has ... American Society for Nutrition (ASN) to publish a ... American Society for Nutrition, and Society for Nutrition ... Adults," focusing on access to safe and adequate ...
... This release is available in Spanish . ... found in South America that can cause terrible, Ebola-like ... Now, Howard Hughes Medical Institute (HHMI) researchers ... hemorrhagic fever virus latches onto and infects human cells, ...
Cached Biology News:Dietary supplements discouraged for prostate cancer patients 2Nutrition services for older adults at home and in communities 2New ways to disarm deadly South American hemorrhagic fever viruses 2New ways to disarm deadly South American hemorrhagic fever viruses 3
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Biology Products: